2'-5'-Oligoadenylate Synthetase 1 (OAS1) and Health Disparities in Prostate Cancer
Total Page:16
File Type:pdf, Size:1020Kb
ABSTRACT DEPARTMENT OF BIOLOGICAL SCIENCES HUNT, AISHA S. B.S. OAKWOOD UNIVERSITY, 2012 2'-5'-OLIGOADENYLATE SYNTHETASE 1 (OAS1) AND HEALTH DISPARITIES IN PROSTATE CANCER Committee Chair: Jaideep Chaudhary, Ph.D. Dissertation dated May 2018 2’ -5’ –oligoadenylate synthetase 1 (OAS1) is an antiviral enzyme that in the presence of double-stranded RNA structures, such as viral genomes or single-stranded RNA transcripts with significant double-stranded character, converts ATP to a series of 2’ -5’ –oligoadenylates (2-5A). 2-5A promotes dimerization of latent ribonuclease (RNaseL) to form catalytically active RNaseL, a candidate hereditary prostate cancer (PCa) gene. RNaseL is anti-proliferative and promotes senescence and apoptosis in PCa cells. Genotyping analysis was completed on over 600 genomic DNA samples from African- American and Caucasian, normal and PCa subjects. Genotyping was performed to screen the following SNPs in the last exon of OAS1 (rs10774671, rs1131476, rs1051042 and rs2660) to determine splicing and linkage disequilibrium (LD) or LD decay in relation to PCa. i The rs10774671 GG and AA genotypes generate isoform 1 (p46) and isoform 3 (p48), respectively and were distributed equally in the healthy population. However, in cases, the AA genotype (p46) was significantly associated with PCa risk (OR: 1.80, P- value: < 0.0001). The genotypic frequencies of rs1131476, rs1051042 and rs2660 demonstrated significant LD but showed no association to PCa risk. We also identified protective (AACA, OR =0.06612, P < 0.001) and risk (GACA, OR= 2.31, p <0.0001) haplotypes from the combined analysis of rs10774671, rs1131476, rs1051042 and rs2660 with PCa. Additionally, we utilized two genome-wide association studies analyzing OAS1 and variants found on chromosome 12 to determine their relationship with PCa susceptibility for meta-analysis: This was done to elucidate the role of OAS1 SNPs and chromosome 12 variants in a larger population cohort with PCa susceptibility for a greater understanding of gene to gene interactions. The genome wide association studies used were, the Geneva Multiethnic Genome-wide Scan of Prostate Cancer (MEC), containing 2,841 African-American samples (1,343 cases and 1,498 controls) and 1,660 Japanese/Latino samples (834 cases and 826 controls), as well as Cancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer-Primary Scan (Stage 1) - PLCO which contains 2,841 samples of European ancestry (1,172 cases and 1,157 controls). We used PLINK, a whole genome association analysis toolset, to extract data on SNPs in association with PCa. ii 2'-5'-OLIGOADENYLATE SYNTHASE 1 (OAS1) AND HEALTH DISPARITIES IN PROSTATE CANCER A DISSERTATION SUBMITTED TO THE FACULTY OF CLARK ATLANTA UNIVERSITY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY BY AISHA S. HUNT DEPARTMENT OF BIOLOGICAL SCIENCES ATLANTA, GEORGIA MAY 2018 © 2018 AISHA S. HUNT All Rights Reserved ACKNOWLEDGEMENTS I would first like to thank my Lord and Savior, Jesus Christ. I would have not made it through these past five years without my faith, His mercy, and grace on this path that He set before me. He is the Author and Editor of my life and He has great plans for me. I want to thank my mentor Dr. Jaideep Chaudhary, for whose patience and trust in my ability I am eternally grateful. I could not have asked for a better mentor in my doctoral pursuit and am truly honored to call myself his pupil. I would also like to thank my committee members: Dr’s. Joanne Powell, Carlos Moreno, Cimona Hinton, and Nathan Bowen. Their constructive criticism, comments, support and suggestions have been invaluable to me. In addition, I am thankful to all members of Dr. Chaudhary’s laboratory, both current and former graduate students, and to the faculty and staff in the Department of Biological Sciences. Their support in my research, as well as their involvement in the many collaborative projects, has given me first-hand knowledge of the importance of collaboration to the scientific process. This work was supported in part by the National Institute of Health Grants: NIH/NIGMS/RISE R25GM060414 and NIH/NIMHD MD002285 (P20). I would finally like to thank my incredible support system, Toney and Norma Hunt, Melissa Grant and her sons (Xavier and Khairi), Sheereen A. Burton, MBA, PMP, CSPO, and Jessica N.S. Cartwright, DPT and many others that I wish I could list. I pray for God to bless my efforts so that I can return those blessings to you all. iii TABLE OF CONTENTS ACKNOWLEDGEMENTS ............................................................................................... iii LIST OF FIGURES ......................................................................................................... viii LIST OF TABLES ............................................................................................................. ix LIST OF ABBREVIATIONS ..............................................................................................x CHAPTER 1. INTRODUCTION .............................................................................................1 2. LITERATURE REVIEW ..................................................................................3 2.1 Prostate and Prostate Cancer ........................................................................3 2.1.1 Risk Factors of Prostate Cancer ..........................................................5 2.1.2 Genetic Disposition in Prostate Cancer Progression ..........................5 2.1.3 Single Nucleotide Polymorphisms in Prostate Cancer and Genome Wide Association Studies ....................................................6 2.1.4 Haplotypes and Linkage Disequilibrium in Prostate Cancer ..............7 2.2 Inflammation in PCa ...................................................................................8 2.2.1 Interferon (IFN) and IFN Pathway in Prostate Cancer ......................... 9 2.2.2 RNaseL ..................................................................................................... 11 2.2.3 Upstream Regulators of RNaseL ......................................................11 2.3 2’-5’ Oligoadenylate Synthetase (OAS) Gene Family ................................. 12 2.3.1 2’-5’ Oligoadenylate Synthetase1 (OAS1) ......................................... 13 2.3.2 2’-5’ Oligoadenylate Synthetase 1 (OAS1) Function and Structure 15 iv CHAPTER 2.3.3 OAS1 Activation by Cellular mRNA ................................................... 16 2.4 Genetic Variation (Single Nucleotide Polymorphism) in OAS1.................. 16 2.4.1 2-5 OAS1 Haplotype Block .............................................................17 2.4.2 OAS1 Enzymatic Activity in Prostate Cancer .................................18 2.5 OAS1 and Disease Associations ..................................................................... 19 2.5.1 OAS1 and Infectious Diseases ............................................................. 20 2.5.2 OAS1 and Aging .................................................................................... 20 2.5.3 OAS1 and Cancer .............................................................................21 3. MATERIALS AND METHODS ...........................................................................22 3.1 Sample Set ...........................................................................................22 3.2 RNA Preparation and RT-PCR ............................................................22 3.3 Genotyping ...........................................................................................23 3.4 SNP Detection ......................................................................................23 3.5 p48 Antibody Production and Purification ..........................................24 3.7 Western Blot Analysis .........................................................................24 3.8 Immunohistochemistry ........................................................................25 3.9 Statistical Analysis ...............................................................................25 3.10 Application and Acquisition of Genome Wide Association Studies (GWAS) ................................................................................26 3.11 GWAS Study Subjects .......................................................................28 3.12 PLINK Hardy Weinberg Equilibrium (HWE). ..................................28 v CHAPTER 3.13 PLINK SNP Minor Allele Frequency ................................................29 3.14 PLINK Case/Control PCa Association ..............................................30 3.15 PLINK Meta-Analysis, Between MEC and CGEMS ........................31 4. RESULTS ..............................................................................................................33 4.1 Sample Set ......................................................................................................33 4.1.1 Frequency of rs10774671 Polymorphisms ......................................33 4.1.2 Frequency of rs1131462, rs1051042, and rs2660 Polymorphisms .36 4.1.3 2-5OAS1 Haplotype Block .............................................................37 4.2 Generation and Characterization of the Rabbit Polyclonal p48 Specific Antibody ............................................................................................39 4.2.1 Expression of 2-5OAS1 Isoforms in Prostate Tissue ......................40 4.3 DbGaP Analysis Outline of OAS1 .................................................................41 4.3.1 GWAS